05.03.2015 • NewsPeopleAdaptimmuneGlaxoSmithKline (GSK)

Adaptimmune Strengthens Management Team with Key Executive Hires

Adaptimmune announced the appointments of Dr. Rafael Amado as Chief Medical Officer and Adrian (Ad) Rawcliffe as Chief Financial Officer, with effect of March 16, 2015.

Dr. Amado will lead Adaptimmune's clinical strategy and assume responsibility for the company's clinical trials across the US and Europe under its strategic collaboration with GlaxoSmithKline (GSK). He will also lead the development of the company's pipeline of wholly-owned research programs. Prior to joining Adaptimmune, Dr. Amado served as Senior Vice President and Head of Oncology R&D at GSK. He joined GSK in 2008 as Vice President of Clinical Development, and served in positions of increasing responsibility, including Senior Vice President and Head of Oncology Clinical Development. Before his time at GSK, Dr. Amado was Executive Director of Therapeutic Oncology at Amgen. He trained as a Hematologist/Oncologist at the University of California, Los Angeles.

Adrian Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management. He joins from GSK where he was Senior Vice President, Finance of its North American Pharmaceuticals business. Prior to this, Rawcliffe held a variety of senior finance and business development roles at GSK, including Senior Vice President Worldwide Business Development and R&D Finance, and Managing Partner and President of SR One, GSK's venture-capital business. He joined GSK in 1998 and holds a BSc degree in Natural Sciences from the University of Durham, UK. He qualified as a Chartered Accountant with Coopers & Lybrand.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read